IVIG Use in Alzheimers

In recent months there has been a growing interest in early and ongoing research into the use of a class of drugs called IVIG (intravenous immune globulin) and its effects on Alzheimer's disease. Although it is too early to form an opinion about its efficacy as an Alzheimer’s disease treatment, several small studies have shown promise which has excited researchers. Particularly of interest is that in some of these studies patients showed actual cognitive improvement not just a slowing or halting of deterioration. This overview of IVIG as an Alzheimer’s medication is intended as an educational piece for patients and clinicians who are interested in Alzheimer’s drugs. Because immunoglobulin therapy is currently available and physicians are already prescribing it for Alzheimer's disease and treatment of dementia, there has been an increased level of interest in it as a new Alzheimer drug. This website and the information contained herein in no way are intended to replace medical advice. If you are a patient or family member, contact your physician and discuss any Alzheimer’s medications or Alzheimer’s treatment with him or her. We will be happy to provide you or your doctor's office any information available to us regarding IVIG and its use for Alzheimers treatment.

Gammagard and it's reported effects in treating patients with Alzheimers

Gammagard May Help Preserve Cognitive Abilities, Reduce Brain Shrinkage In
Patients With Alzheimer's

According to research presented recently at the American Academy of Neurology meeting, the immune-system medication Gammagard (an intravenous immune globulin/IVIG), helped preserve thinking abilities in a small group of patients with Alzheimer's disease. Gammagard is designed to reduce levels of amyloid plaque and also fights inflammation, which is associated with Alzheimer's disease.

To speak with a nurse or pharmacist about IVIG call us toll free at 866.44.BIORX (866.442.4679) or email us.